FOI release
NeuroCytonix
Some or all of the information requested was not provided because we didn't hold it.
Case reference FOI2025/01267
Received 5 December 2025
Published 29 January 2026
Request
I am writing to request information under the Freedom of Information Act 2000. Background / Reason for Request I refer to previous communications indicating that guidance on NeuroCytonix (also referred to as "NeuroCytotron") has not been published by the National Institute for Health and Care Excellence (NICE), and that regulatory licensing and oversight of such treatments is under the remit of your agency, the MHRA. Information Requested 1. Any internal MHRA correspondence, assessments, meeting notes, or other documents (emails, briefings, internal discussions) that refer to NeuroCytonix / NeuroCytotron, Cytotron- or Q-radial-related technology, or any clinical submissions, evaluations or enquiries regarding this technology or treatment. 2. Any external correspondence between MHRA and third parties (e.g. manufacturers, clinicians, members of the public, or other government/health bodies) relating to NeuroCytonix / NeuroCytotron. 3. Any documentation or records explaining MHRA's position or decisions regarding licensing, review or clearance (or refusal thereof) of NeuroCytonix / NeuroCytotron. 4. Any records of communications or referrals from MHRA to other bodies (or from other bodies to MHRA) concerning regulation, licensing or oversight of NeuroCytonix / NeuroCytotron. Please provide the information in electronic format if possible. If fulfilling the request in full would exceed cost or resource limits, I would welcome your guidance on how to narrow it to stay within those limits.
Response
See attached
Documents
This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.